MedTrace Logo

European Drug Utilization Study

NCT01594996 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 814

Last updated 2017-11-01

No results posted yet for this study

Summary

The purpose of this retrospective observational study is to evaluate the characteristics of patients receiving Seroquel XR as treatment for their Major Depressive Disorder. The study will also investigate how the medication is used for these patients and if there are any differences in drug utilisation between the included countries. The study is observing patients initiating Seroquel XR during a 9 month period corresponding to 3 to 12 months following the launch of the product in each country for the MDD indication. A drug utilisation questionnaire will be used to collect study data from patients' medical records.

Conditions

  • Major Depressive Disorder (MDD)

Sponsors & Collaborators

Principal Investigators

  • Hans A Eriksson, MD · AstraZeneca R&D

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-24
Primary Completion
2014-03-27
Completion
2014-03-27

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01594996 on ClinicalTrials.gov